Europe PMC

Purpose Accumulating evidence supports the association between altered salivary microbiota and inflammatory diseases. The existing literature on the salivary microbiota in patients with psoriasis is limited. However, differences in the prevalence of Candida species and abundance of several bacterial taxa in saliva have been found between patients and controls. This study aimed to investigate the differences in the composition and functional potential of salivary microbiota in patients with psori

Psoriasis features keratinocyte hyperproliferation. This study aimed to identify disulfidptosis-related key genes in psoriasis for potential diagnostic biomarkers or therapeutic targets. Using the GSE30999 dataset, WGCNA was applied to identify key gene modules. GO, KEGG were used for analysis. IHC, Western blot, PCR and free thiol tests verified results. WGCNA clustered differentially expressed genes into 18 modules, with the blue module being significantly associated with psoriasis (Pearson's

Objective This study evaluated psoriasis treatment teaching in dermatology residency programs across Latin America (LATAM).Methods A Spanish/Portuguese survey was distributed to directors of dermatology departments/training programs and their residents in several LATAM countries between November 29, 2022, and March 31, 2023.Results A total of 108 individuals responded (59 directors and 49 residents) from eight countries: Argentina (2.8%), Brazil (41.7%), Chile (25.0%), Colombia (7.4%), Guatemala

Despite advances in the treatment of psoriatic arthritis (PsA), a substantial proportion of patients continue to report persistent symptoms and impaired quality of life. However, terminology remains inconsistent for patients who fail to achieve disease control despite treatment, which limits research comparability and contributes to therapeutic inertia. To address this gap, a Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) task force developed consensus definition

No abstract supplied.Weiterlesen

Advances in the understanding of the pathophysiology of psoriasis have led to the development of biologic therapies that target key components of the immune system involved in the inflammatory cascade of psoriasis, revolutionizing the management of moderate-to-severe cases. Alongside biologics, small molecules have emerged as promising treatment options. However, despite significant progress, several challenges remain. Additionally, long-term safety data for many newer agents are still lacking,

No abstract supplied.Weiterlesen

Psoriasis involving the genital region (GenPsO) is associated with impaired quality of life (QoL), including sexual burden and avoidance of sexual intercourse. There is limited data on the effectiveness of risankizumab in GenPsO on patients' QoL and sexual impairment. GPS-Best, a nested cohort non-interventional study within the German Psoriasis registry PsoBest, aims to evaluate the effectiveness of risankizumab in GenPsO and its impact on QoL and sexual impairment. This interim analysis involv

Background Conventional systemic agents remain the cornerstone treatment for psoriasis because of their availability and cost-effectiveness. However, few studies have compared the effectiveness and drug persistence of these agents in Asian populations.Objectives To evaluate the effectiveness and drug persistence of methotrexate, cyclosporine, and acitretin, and to identify factors associated with these outcomes.Methods We reviewed data from 338 psoriasis patients treated with methotrexate, cyclo

Objectives Sternoclavicular joint (SCJ) involvement in psoriatic arthritis (PsA) is poorly characterized. We aimed to assess its prevalence and clinical associations in a longitudinal PsA cohort.Methods We retrospectively analyzed prospectively collected data from the Gladman Krembil Psoriatic Arthritis Program. Patients with SCJ involvement (tender and/or swollen SCJ) were identified, and their demographic, clinical, laboratory, and treatment details were retrieved. Univariable and multivariabl

Psoriasis is a chronic skin disease mediated by Th1 and Th17 immune responses and is classified as a systemic inflammatory disorder. Notably, psoriasis is an independent risk factor for myocardial infarction, stroke, and cardiovascular mortality, particularly in severe disease. However, the cellular mechanisms linking psoriasis to cardiovascular disease have not yet been identified. To address this gap, we investigated systemic markers of inflammasome signaling and innate immune activation in pa

No abstract supplied.Weiterlesen

Background: /Objectives: Plaque psoriasis is a chronic immune-mediated inflammatory disease affecting approximately 3% of the global population and resulting in a significant deterioration in quality of life. Systemic therapy with monoclonal antibodies (mAbs) targeting TNF-α, IL-23, and IL-17 improves clinical outcomes and patients’ quality of life. Treatment strategies commonly include different mAbs and different sequencings approaches between agents, which are well-established in clinical p

Background Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with IL-17 or IL-23 inhibitors, evidence for this practice is weak.Objectives To review evidence on safety of IL-17 and IL-23 inhibitors in the setting of latent TB infection, and to provide a new Joint Position Statement on this topic.Methods Experts from the National Psoriasis Foundation (NPF) and the International Psoriasis Council (IPC) reviewed evidence regardin

No abstract supplied.Weiterlesen

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory arthritis associated with psoriasis, affecting joints, entheses, and the axial skeleton. While primary care providers and dermatologists frequently encounter psoriasis (PsO), early recognition of PsA remains critical to preventing irreversible joint damage. This paper is written to provide a comprehensive overview of PsA, beginning with a clinical case that highlights diagnostic and therapeutic challenges. In this review, the e

No abstract supplied.Weiterlesen

Introduction Delays remain in patients receiving effective treatment strategies that have potential to clear their skin of psoriasis, improve their quality of life (QoL) and change the psoriatic disease course, which, if uncontrolled, can irreversibly alter an individual's life course (i.e. cumulative life course impairment [CLCI]). This study explored current international awareness and consideration of the potential impact of psoriasis over the life course within clinical assessments and decis

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Sternoclavicular joint (SCJ) involvement in psoriatic arthritis (PsA) is poorly characterized. We aimed to assess its prevalence and clinical associations in a longitudinal PsA cohort. We retrospectively analyzed prospectively collected data from the Gladman Krembil Psoriatic Arthritis Program. Patients with SCJ involvement (tender and/or swollen SCJ) were identified, and their demographic, clinical, laboratory, and treatment details were retrieved. Univariable and multivariable generalized esti

Psoriasis is a systemic immune‑mediated skin disease, typically considered to be incurable. Identification of meaningful biomarkers has been a notable challenge in psoriasis prevention and management. The present study aimed to determine the signature genes driving psoriasis and their underlying mechanism. Microarray datasets of psoriasis were obtained from the Gene Expression Omnibus database, and the differentially expressed genes (DEGs) were identified using the 'limma' R package. Gene Set En

Atherosclerosis is now considered to reflect systemic inflammation involving the elevation of multiple proinflammatory cytokines, sharing common underlying pathophysiological mechanisms with psoriasis. There has been increasing interest in whether anti-inflammatory treatment of psoriasis can prevent or halt the progression of atherosclerosis. Here, we conducted a cross-sectional observational clinical study in psoriasis patients with at least one traditional cardiovascular risk factor, such as d

Psoriasis is a prevalent chronic inflammatory skin disease that significantly reduces patients' quality of life. Current treatments have limited efficacy and severe side effects, necessitating the development of new drugs. Notopterygii rhizoma et radix (Qiang Huo, QH), a Traditional Chinese Medicine (TCM) herb commonly studied for psoriasis patterns and treatment, requires further clarifications of its pharmacological mechanism. This study first verified the therapeutic effects of QH on Imiquimo

No abstract supplied.Weiterlesen